Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ovarian Clear Cell Adenocarcinoma Review (OCCA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02129036
Recruitment Status : Completed
First Posted : May 2, 2014
Last Update Posted : August 9, 2019
Sponsor:
Collaborator:
National Taiwan University Hospital
Information provided by (Responsible Party):
Chih-Ming Ho, Cathay General Hospital

Brief Summary:
Clear cell carcinoma comprises 5-10% of surface epithelial ovarian cancers, and about 30-40% of the patients with clear cell carcinoma are diagnosed in the advanced stage. The investigators studied the response to chemotherapy and survival for either paclitaxel-platinum based chemotherapy or conventional platinum-based chemotherapy among all stages clear cell ovarian carcinoma. Prognostic factors for survival among the patients with pure, advanced, clear cell ovarian carcinoma were also evaluated.

Condition or disease
Ovarian Cysts

Detailed Description:
  1. Several authors have reported frequent admixtures of clear cell ovarian carcinoma with serous, mucinous, and endometrioid tumors. However, few papers addressed the difference in response to chemotherapy and survival between patients with pure and mixed-type advanced clear cell carcinoma.
  2. Recent trends in the clinical management of advanced ovarian cancer include increased attention to maximal cytoreduction and general acceptance of paclitaxel-platinum-based adjuvant chemotherapy.
  3. The introduction of paclitaxel markedly changed the postoperative management of ovarian cancer patients, but the results and value of these newer efforts and therapies applied to clear cell carcinoma are as yet undetermined.
  4. Today, paclitaxel-platinum-based chemotherapy is becoming the standard regimen for ovarian cancer worldwide. Previous research suggests a potential benefit of paclitaxel plus carboplatin regimens for stage I clear cell carcinoma. However, few papers specifically addressed the efficacy of paclitaxel-platinum-based chemotherapy for advanced clear cell carcinoma because clear cell carcinoma occurs only rarely in Western countries.

Layout table for study information
Study Type : Observational
Actual Enrollment : 5 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Retrospective Multi-institutional Survey of Clinical Characteristics in Ovarian Clear Cell Adenocarcinoma Cancer Patients
Study Start Date : April 2008
Actual Primary Completion Date : December 2012
Actual Study Completion Date : December 2013





Primary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: Overall survival (up to 6 years) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
total 300 patients of ovarian clear cell carcinoma post operation from 8 institution.
Criteria

Inclusion Criteria:

  • Clinical diagnosis of Ovarian clear cell carcinoma

Exclusion Criteria:

  • not undergo operation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02129036


Sponsors and Collaborators
Cathay General Hospital
National Taiwan University Hospital
Investigators
Layout table for investigator information
Study Director: Chih-Ming Ho Gynecologic Cancer Center, Cathay general Hospital

Layout table for additonal information
Responsible Party: Chih-Ming Ho, Dr, Cathay General Hospital
ClinicalTrials.gov Identifier: NCT02129036     History of Changes
Other Study ID Numbers: TGOG-127
First Posted: May 2, 2014    Key Record Dates
Last Update Posted: August 9, 2019
Last Verified: April 2014

Keywords provided by Chih-Ming Ho, Cathay General Hospital:
Ovarian cancer
Clear cell carcinoma
Paclitaxel-platinum
Chemotherapy
response to chemotherapy
survival of clear cell ovarian carcinoma
Prognostic factors

Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Adenocarcinoma, Clear Cell
Ovarian Cysts
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Cysts
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases